From MarketBeat:

CureVac Stock Sinks

Despite a large drop in short interest in December, CureVac’s stock trades down 1.6% to $4.21 per share. November 30th saw 4.1% of the company’s shares sold short and a total of 4,240,000 shares. As of December 15th, short interest totaled 3,750,000 shares.

The company’s current shares are 3.7 days’ worth of trading. Hedge funds and investors have shown mixed support for the company, with fifteen percent of the stock currently owned by outside investors.

About CureVac

Use Bancorp DE and China Universal Asset Management Co. have also added to their stakes in the company. This news was immediately generated by narrative science technology and financial data from MarketBeat. MarketBeat’s editorial team has also reviewed the story. Should you consider investing in CureVac or another stock? Please read on to find out more.

If you’re considering investing in CureVac, please send any questions or comments about the story to [email protected]. MarketBeat has also identified five stocks that top analysts are quietly recommending to their clients. While CureVac currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

Read more: CureVac (NASDAQ:CVAC) Short Interest Down 11.6% in December